ABVX vs CYTK
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ABVX · Abivax S.A.$73.20 ▼ 9.24%
CYTK · Cytokinetics$50.78 ▼ 1.32%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ABVX -41.8%
- CYTK -24.4%
Head to head
| Metric | ABVX | CYTK |
|---|---|---|
| Price | $73.20 | $50.78 |
| Change today | ▼ 9.24% | ▼ 1.32% |
| Market cap | $6.41B | $7.07B |
| Return, 3 months | -37.0% | -34.1% |
| Return, year to date | -45.7% | -20.1% |
| Return, 1 year | -38.5% | -22.4% |
| P/E (TTM) | – | – |
| P/B | 16.0 | -22.0 |
| P/E percentile vs own 5y | 55th | 65th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +2,356.5% |
| Net profit growth (YoY) | -142.6% | +37.9% |
| Gross margin | – | 95.3% |
| Operating margin | – | -625.2% |
| Net margin | – | -686.6% |
| Return on equity | -252.3% | – |
| Analyst target vs. price | +119.3% | +111.3% |
| Analyst buy share | 89% | 94% |
| RSI (14) | 30 | 30 |
| 30-day volatility | 54.8% | 52.6% |
| Max drawdown, 1 year | -50.1% | -41.8% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CYTK is the largest of the group by market value.
- CYTK has returned the most over the past year.
- CYTK has been the calmest stock over the last 30 days.